Platelet receptors for adenine nucleotides and thromboxane A 2

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 4, 2004, Pages 411-418

  Murugappan, Swaminathan ^b   Shankar, Haripriya ^b   Kunapuli, Satya P ^a,b  

^a TEMPLE UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

P2X 1 receptor; P2Y 12 receptor; P2Y 1 receptor; Platelet function

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ADENINE NUCLEOTIDE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BM 573; CELL SURFACE RECEPTOR; CLOPIDOGREL; FIBRINOGEN RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; IFETROBAN; PHOSPHOLIPASE C; PURINE P2X1 RECEPTOR; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR; RECEPTOR SUBTYPE; THROMBOCYTE RECEPTOR; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; VAPIPROST;

ARTERIOLE; BLEEDING TIME; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; DESENSITIZATION; ENZYME ACTIVATION; GENE DISRUPTION; HEART INFARCTION; HEMOSTASIS; HUMAN; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOGENESIS;

ADENINE NUCLEOTIDES; ANIMALS; BLOOD PLATELETS; HUMANS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; RECEPTORS, PURINERGIC P2; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2;

EID: 4444313230     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-833476     Document Type: Review

References (82)

1. Packham MA. Role of platelets in thrombosis and hemostasis. Can J Physiol Pharmacol 1994;72:278-284
2. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999;19:2281-2285
3. Bennett JS. Novel platelet inhibitors. Annu Rev Med 2001; 52:161-184
4. FitzGerald GA, Mayo G, Price P, Takahara K. Aspirin in cardiovascular disease; biochemical pharmacology and clinical trials. Prog Clin Biol Res 1989;301:97-106
5. Kunapuli SP, Dorsam RT, Kim S, Quinton TM. Platelet purinergic receptors. Curr Opin Pharmacol 2003;3:175-180
6. MacKenzie AB, Mahaut-Smith MP, Sage SO. Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets. J Biol Chem 1996;271: 2879-2881
7. Vial C, Hechler B, Leon C, Cazenave JP, Gachet C. Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost 1997;78:1500-1504
8. Sun B, Li J, Okahara K, Kambayashi J. P2X1 purinoceptor in human platelets. Molecular cloning and functional characterization after heterologous expression. J Biol Chem 1998;273: 11544-11547
9. Mahaut-Smith MP, Ennion SJ, Rolf MG, Evans RJ. ADP is not an agonist at P2X(1) receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 2000;131:108-114
10. Jacobson KA, Kim YC, Wildman SS, et al. A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. J Med Chem 1998;41:2201-2206
11. Vial C, Rolf MG, Mahaut-Smith MP, Evans RJ. A study of P2X1 receptor function in murine megakaryocytes and human platelets reveals synergy with P2Y receptors. Br J Pharmacol 2002;135:363-372
12. Takano S, Kimura J, Matsuoka I, Ono T. No requirement of P2X1 purinoceptors for platelet aggregation. Eur J Pharmacol 1999;372:305-309
13. Rolf MG, Brearley CA, Mahaut-Smith MP. Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. Thromb Haemost 2001;85: 303-308
14. Rolf MG, Mahaut-Smith MP. Effects of enhanced P2X1 receptor Ca2+ influx on functional responses in human platelets. Thromb Haemost 2002;88:495-502
15. Oury C, Toth-Zsamboki E, Thys C, et al. The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemost 2001;86:1264-1271
16. Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF. P2X(1)-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen. Blood 2002;100:2499-2505
17. Toth-Zsamboki E, Oury C, Cornelissen H, De Vos R, Vermylen J, Hoylaerts MF. P2X1 mediated ERK2 activation amplifies the collagen induced platelet secretion by enhancing myosin light chain kinase activation. J Biol Chem 2003; 278:46661-46667
18. Hechler B, Lenain N, Marchese P, et al. A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med 2003;198:661-667
19. Oury C, Kuijpers MJ, Toth-Zsamboki E, et al. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood 2003; 101:3969-3976
20. Ayyanathan K, Webbs TE, Sandhu AK, et al. Cloning and chromosomal localization of the human P2Y1 purinoceptor. Biochem Biophys Res Commun 1996;218:783-788
21. Leon C, Vial C, Cazenave JP, Gachet C. Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor. Gene 1996;171:295-297
22. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998;273:2030-2034
23. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha(q)-deficient mice. Nature 1997; 389:183-186
24. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998;95:8070-8074
25. Dangelmaier C, Jin J, Daniel JL, Smith JB, Kunapuli SP. The P2Y1 receptor mediates ADP-induced p38 kinase-activating factor generation in human platelets. Eur J Biochem 2000; 267:2283-2289
26. Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood 2002;99:193-198
27. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001; 12:443-447
28. Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001;98:3340-3345
29. Remijn JA, Wu YP, Jeninga EH, et al. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002;22:686-691
30. Leon C, Hechler B, Freund M, et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest 1999; 104:1731-1737
31. Fabre JE, Nguyen M, Latour A, et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 1999; 5:1199-1202
32. Hechler B, Zhang Y, Eckly A, et al. Lineage-specific overexpression of the P2Y1 receptor induces platelet hyperreactivity in transgenic mice. J Thromb Haemost 2003;1:155-163
33. Leon C, Freund M, Ravanat C, et al. Key role of the P2Y(1) receptor in tissue factor-induced thrombin- dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation 2001; 103:718-723
34. Lenain N, Freund M, Leon C, Cazenave JP, Gachet C. Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost 2003;1:1144-1149
35. Kunapuli SP, Ding Z, Dorsam RT, et al. ADP receptors-targets for developing antithrombotic agents. Curr Pharm Des 2003;9:2303-2316
36. Ohlmann P, Laugwitz KL, Nurnberg B, et al. The human platelet ADP receptor activates Gi2 proteins. Biochem J 1995; 312(pt 3):775-779
37. Takasaki J, Kamohara M, Saito T, et al. Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol 2001;60:432-439
38. Zhang FL, Luo L, Gustafson E, et al. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem 2001;276:8608-8615
39. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-207
40. Savi P, Labouret C, Delesque N, et al. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001;283:379-383
41. Daniel JL, Dangelmaier C, Jin J, et al. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998;273:2024-2029
42. Daniel JL, Dangelmaier C, Jin J, Kim YB, Kunapuli SP. Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb Haemost 1999;82:1322-1326
43. Dangelmaier C, Jin J, Smith JB, Kunapuli SP. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost 2001;85:341-348
44. Paul BZ, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem 1999; 274:29108-29114
45. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992;80:2787-2796
46. Jung SM, Moroi M. Activation of the platelet collagen receptor integrin alpha(2)beta(1): its mechanism and participation in the physiological functions of platelets. Trends Cardiovasc Med 2000;10:285-292
47. Storey RF, Sanderson HM, White AE, et al. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000;110:925-934
48. Ohlmann P, Eckly A, Freund M, et al. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood 2000;96:2134-2139
49. Quinton TM, Kim S, Dangelmaier C, et al. Protein kinase C-and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation. Biochem J 2002;368:535-543
50. Wagner WR, Hubbell JA. ADP receptor antagonists and converting enzyme systems reduce platelet deposition onto collagen. Thromb Haemost 1992;67:461-467
51. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002;13:407-413
52. Larson MK, Chen H, Kahn ML, et al. Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets. Blood 2003; 101:1409-1415
53. Atkinson BT, Stafford MJ, Pears CJ, Watson SP. Signalling events underlying platelet aggregation induced by the glycoprotein VI agonist convulxin. Eur J Biochem 2001;268: 5242-5248
54. Dorsam RT, Kim S, Jin J, Kunapuli SP. Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets. J Biol Chem 2002;277:47588-47595
55. Nieswandt B, Schulte V, Zywietz A, Gratacap MP, Offermanns S. Costimulation of Gi- and G12/G13-mediated signaling pathways induces integrin alpha IIbbeta 3 activation in platelets. J Biol Chem 2002;277:39493-39498
56. Goto S, Tamura N, Eto K, Ikeda Y, Handa S. Functional significance of adenosine 5′-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation 2002;105:2531-2536
57. van Gestel MA, Heemskerk JW, Slaaf DW, et al. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol 2003;23:518-523
58. Dorsam RT, Murugappan S, Ding Z, Kunapuli SP. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance. Hematology (Am Soc Hematol Educ Program) 2003;8:359-365
59. Leon C, Ravanat C, Freund M, Cazenave JP, Gachet C. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 2003;23:1941-1947
60. Leon C, Alex M, Klocke A, et al. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood 2003;103:594-600
61. Jantzen HM, Milstone DS, Gousset L, Conley PB, Mortensen RM. Impaired activation of murine platelets lacking G alpha(i2). J Clin Invest 2001;108:477-483
62. Kauffenstein G, Bergmeier W, Eckly A, et al. The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin-a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett 2001;505:281-290
63. Hirsch E, Bosco O, Tropel P, et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J 2001;15:2019-2021
64. Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001;107:1591-1598
65. Andre P, Delaney SM, LaRocca T, et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003;112:398-406
66. Samuelsson B, Goldyne M, Granstrom E, et al. Prostaglandins and thromboxanes. Annu Rev Biochem 1978;47:997-1029
67. Kobayashi T, Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat 2002;68-69:557-573
68. Ushikubi F, Nakajima M, Hirata M, et al. Purification of the thromboxane A2/prostaglandin H2 receptor from human blood platelets. J Biol Chem 1989;264:16496-16501
69. Arita H, Nakano T, Hanasaki K. Thromboxane A2: its generation and role in platelet activation. Prog Lipid Res 1989;28:273-301
70. Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 1996;97:949-956
71. Habib A, FitzGerald GA, Maclouf J. Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem 1999;274:2645-2651
72. Miggin SM, Kinsella BT. Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta 1998;1425:543-559
73. Shenker A, Goldsmith P, Unson CG, Spiegel AM. The G protein coupled to the thromboxane A2 receptor in human platelets is a member of the novel Gq family. J Biol Chem 1991;266:9309-9313
74. Knezevic I, Borg C, Le Breton GC. Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/prostaglandin H2 receptors. J Biol Chem 1993;268:26011-26017
75. Kinsella BT, O'Mahony DJ, Fitzgerald GA. The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther 1997;281:957-964
76. Offermanns S, Laugwitz KL, Spicher K, Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci USA 1994;91:504-508
77. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991;68:11B-15B
78. Takahara K, Murray R, FitzGerald GA, Fitzgerald DJ. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem 1990;265:6836-6844
79. Thomas DW, Mannon RB, Mannon PJ, et al. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 1998;102:1994-2001
80. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119:39S-63S
81. Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. Chest 2001;119:228S-252S
82. Rolin S, Petein M, Tchana-Sato V, et al. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis. J Pharmacol Exp Ther 2003;306: 59-65